Brahmi (Bacopa Monnieri Linn) in the treatment of dementia

Update l'année dernière
Reference: ISRCTN18407424

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -


Background and study aims People are living longer than ever before and the incidence of Alzheimer’s disease (AD) and other age-related dementias continues to increase worldwide; no treatment is available to reverse or even at least to halt satisfactorily the underlying pathology of established AD. The objective/aim of the study was to determine whether an extract of Brahmi (Bacopa monnieri Linn) could be useful in different types of dementia. Brahmi (Bacopa monnieri Linn) is a herb used traditionally in India as a memory-enhancer. We studied its effect on human memory and forgetfulness in dementia of various grades - from mild to severe. There are reports of its efficacy in various publications: Many relate to its effect in animals, some to its effect in human beings too. One such study showed that it decreased the rate of forgetting newly acquired information in humans while the rate of learning remained unaffected. None of the reports specifically mentions its effect in dementias. We decided to conduct a pilot study, thus laying the framework for definitive studies. Who can participate? Patients with dementia over the age of 18. What does the study involve? All participants are given Brahmi (Himalaya) 250 mg to take twice a day for three months. Before starting treatment and then after three months, participants complete a number of questionnaires in order to find out how bad their AD is, and if they have experienced any falls. What are the possible benefits and risks of participating? Participants may benefit from an improvement to their cognitive function, especially their memory. There is a small risk of experiencing bloating after taking Brahmi, but this is very mild. Where is the study run from? Ambalike Clinic (India) When is study starting and how long is it expected to run for? June 2015 to May 2016 Who is funding the study? Ambalike Clinic (India) Who is the main contact? 1. Professor Mohan Mishra (scientific) 2. Dr Ajay Kumar Mishra (public)

Inclusion criteria

  • Dementia